• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell . An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies

tetano

Editor, Senior Moderator
Cell


. 2021 May 24;S0092-8674(21)00662-0.
doi: 10.1016/j.cell.2021.05.032. Online ahead of print.
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies


Yafei Liu[SUP] 1 [/SUP], Wai Tuck Soh[SUP] 2 [/SUP], Jun-Ichi Kishikawa[SUP] 3 [/SUP], Mika Hirose[SUP] 3 [/SUP], Emi E Nakayama[SUP] 4 [/SUP], Songling Li[SUP] 5 [/SUP], Miwa Sasai[SUP] 6 [/SUP], Tatsuya Suzuki[SUP] 7 [/SUP], Asa Tada[SUP] 2 [/SUP], Akemi Arakawa[SUP] 2 [/SUP], Sumiko Matsuoka[SUP] 8 [/SUP], Kanako Akamatsu[SUP] 9 [/SUP], Makoto Matsuda[SUP] 10 [/SUP], Chikako Ono[SUP] 11 [/SUP], Shiho Torii[SUP] 11 [/SUP], Kazuki Kishida[SUP] 2 [/SUP], Hui Jin[SUP] 8 [/SUP], Wataru Nakai[SUP] 1 [/SUP], Noriko Arase[SUP] 12 [/SUP], Atsushi Nakagawa[SUP] 13 [/SUP], Maki Matsumoto[SUP] 14 [/SUP], Yukoh Nakazaki[SUP] 14 [/SUP], Yasuhiro Shindo[SUP] 14 [/SUP], Masako Kohyama[SUP] 1 [/SUP], Keisuke Tomii[SUP] 13 [/SUP], Koichiro Ohmura[SUP] 15 [/SUP], Shiro Ohshima[SUP] 16 [/SUP], Toru Okamoto[SUP] 17 [/SUP], Masahiro Yamamoto[SUP] 18 [/SUP], Hironori Nakagami[SUP] 19 [/SUP], Yoshiharu Matsuura[SUP] 20 [/SUP], Atsushi Nakagawa[SUP] 21 [/SUP], Takayuki Kato[SUP] 3 [/SUP], Masato Okada[SUP] 22 [/SUP], Daron M Standley[SUP] 23 [/SUP], Tatsuo Shioda[SUP] 24 [/SUP], Hisashi Arase[SUP] 25 [/SUP]



Affiliations

Abstract

Antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein prevent SARS-CoV-2 infection. However, the effects of antibodies against other spike protein domains are largely unknown. Here, we screened a series of anti-spike monoclonal antibodies from coronavirus disease 2019 (COVID-19) patients and found that some of antibodies against the N-terminal domain (NTD) induced the open conformation of RBD and thus enhanced the binding capacity of the spike protein to ACE2 and infectivity of SARS-CoV-2. Mutational analysis revealed that all of the infectivity-enhancing antibodies recognized a specific site on the NTD. Structural analysis demonstrated that all infectivity-enhancing antibodies bound to NTD in a similar manner. The antibodies against this infectivity-enhancing site were detected at high levels in severe patients. Moreover, we identified antibodies against the infectivity-enhancing site in uninfected donors, albeit at a lower frequency. These findings demonstrate that not only neutralizing antibodies but also enhancing antibodies are produced during SARS-CoV-2 infection.

Keywords: ADE; angiotensin converting enzyme 2; antibody-dependent enhancement; cryo-EM; cryo-electron microscopy; docking model.
 
Back
Top Bottom